Mammoth

Mammoth, a San Francisco-based CRISPR diagnostics company, has raised $271 million across multiple rounds, including a $150 million Series D led by Redmile Group and Foresite Capital. With a $1 billion valuation (as of September 2021), the company leverages Cas12 and Cas13 proteins to develop next-gen molecular diagnostics for healthcare, agriculture, and industrial applications. Backed by top investors like Mayfield, Decheng Capital, and the National Institutes of Health, Mammoth aims to redefine disease detection and gene-based therapeutics through precision CRISPR technology.